The DOI matches its Crossref record.
Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)
Abstract
LBA4510 Background: BAY 43–9006 (BAY), a dual-action Raf kinase and VEGFR inhibitor, inhibits tumor cell proliferation and angiogenesis. In Phase II trials, BAY has demonstrated activity in patients (pts) with metastatic RCC. The primary aim of this Phase III, double-blind trial was to assess overall survival (OS) in pts with confirmed advanced clear-cell RCC randomized to BAY vs best supportive care (BSC). Results of a planned analysis on the secondary endpoint, progression free survival (PFS) will be presented in this report. Methods: Pts (ECOG 0–1) who had received one prior systemic therapy for advanced RCC were stratified into intermediate- (1–2 risk factors) or low-risk (no risk factors) groups, according to the MSKCC prognostic index. Pts were randomized to receive continuous BAY 400 mg bid or matched placebo with BSC. Pts were withdrawn from the study if they met any of the following criteria: AEs requiring study drug termination; progressive disease (unless continued treatment was considered appropriate by the investigator); patient/sponsor request; pt lost to follow-up; or death. The primary efficacy endpoint is OS, for which an overall two-sided alpha of 0.04 will be used. Final analysis of OS will be performed after 540 events, required to detect 33% improvement with 90% power. Provided interim monitoring boundaries are not crossed, 884 pts (442 per treatment arm) will be randomized. PFS will be compared at a two-sided alpha level of 0.01 using a log-rank test stratified by prognostic group and country. Adverse events will be tabulated by NCI CTC version 3.0. Results: To date, 611 out of 884 pts have been randomized and 229 PFS events have occurred. PFS analysis will be performed after 363 progressive events have occurred. The results of the PFS analysis and the safety experience will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer Healthcare Antigenics, Bayer, CFSB, Deutsche Bank, Genentech, Medacorp, Pfizer, Roche AstraZeneca, Bayer AG Antigenics, Bayer, Centocor, Genentech, Pfizer, Roche, Wyeth Amgen, Antigenics, Bayer, Celgene, Genentech, Pfizer, Wyeth
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Rini, B. I., Bukowski, R. M., Curti, B. D., George, D. J., Hudes, G. R., Redman, B. G., Margolin, K. A., Merchan, J. R., Wilding, G., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2516 · Cited by 1,230
Self-citationRatain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., Gore, M., Desai, A. A., Patnaik, A., Xiong, H. Q., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6723 · Cited by 1,032
Self-citationGupta, K., Miller, J. D., Li, J. Z., Russell, M. W., & Charbonneau, C. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.12.001 · Cited by 974
Sunitinib: From Rational Design to Clinical Efficacy
Chow, L. Q. M., & Eckhardt, S. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3602 · Cited by 883
Metadata
- Authors
- Escudier, B., Szczylik, C., Eisen, T., Stadler, W. M., Schwartz, B., Shan, M., & Bukowski, R. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-06
- Volume
- 23
- Issue
- 16_suppl
- Pages
- LBA4510-LBA4510
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2305352133
- Cited by
- 348
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). https://app.cochat.ai/papers/10.1200/jco.2005.23.16_suppl.lba4510
- The paper
- Escudier, B., Szczylik, C., Eisen, T., Stadler, W. M., Schwartz, B., Shan, M., & Bukowski, R. M. (2005). Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.23.16_suppl.lba4510
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.